Objective: Nosocomial diarrhea is a major problem in pediatric hospitals worldwide. We evaluated the efficacy of orally administered Lactobacillus GG (LGG) in the prevention of this disease in young children.
Study design: Eighty-one children aged 1 to 36 months who were hospital- ized for reasons other than diarrhea were enrolled in a double-blind trial and randomly assigned at admission to receive LGG (n = 45) at a dose of 6 × 109 colony-forming units or a comparable placebo (n = 36) twice daily orally for the duration of their hospital stay.
Results: LGG reduced the risk of nosocomial diarrhea (≥3 loose or watery stools/24 h) in comparison with placebo (6.7% vs 33.3%; relative risk: 0.2; [95% CI: 0.06–0.6]; number needed to treat: 4 [95% CI: 2–10]). The preva- lence of rotavirus infection was similar in LGG and placebo groups (20% vs 27.8%, respectively; relative risk: 0.72; 95% CI: 0.33–1.56). However, the use of LGG compared with placebo significantly reduced the risk of ro- tavirus gastroenteritis (1/45 [2.2%] vs 6/36 [16.7%], respectively; relative risk: 0.13; 95% CI: 0.02–0.79; number needed to treat: 7; 95% CI: 3–40).
Conclusions: Prophylactic use of LGG significantly reduced the risk of nosocomial diarrhea in infants, particularly nosocomial rotavirus gastroen- teritis. (J Pediatr 2001;138:361-5)
Download File: Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infants